Jacobs Levy Equity Management Inc. Reduces Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

Jacobs Levy Equity Management Inc. lowered its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 10.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,326,391 shares of the company’s stock after selling 153,465 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Acelyrin were worth $6,539,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in shares of Acelyrin by 1.3% during the first quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock worth $42,103,000 after acquiring an additional 81,633 shares in the last quarter. Millennium Management LLC lifted its position in shares of Acelyrin by 15.7% during the second quarter. Millennium Management LLC now owns 4,642,056 shares of the company’s stock worth $20,471,000 after acquiring an additional 628,528 shares in the last quarter. Blue Owl Capital Holdings LP lifted its position in shares of Acelyrin by 3.5% during the second quarter. Blue Owl Capital Holdings LP now owns 2,926,028 shares of the company’s stock worth $12,904,000 after acquiring an additional 100,000 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Acelyrin by 81.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 609,678 shares of the company’s stock worth $3,006,000 after acquiring an additional 273,604 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Acelyrin by 218.0% during the second quarter. Renaissance Technologies LLC now owns 397,618 shares of the company’s stock worth $1,753,000 after acquiring an additional 272,600 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on SLRN shares. HC Wainwright increased their target price on Acelyrin from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. Morgan Stanley lowered their price objective on Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Monday, August 19th. Piper Sandler lowered their price objective on Acelyrin from $68.00 to $20.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company increased their price objective on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.40.

Acelyrin Stock Down 0.7 %

SLRN opened at $4.21 on Friday. The stock has a market cap of $422.39 million, a PE ratio of -1.71 and a beta of 1.61. Acelyrin, Inc. has a 52 week low of $3.36 and a 52 week high of $8.89. The business’s fifty day simple moving average is $5.32 and its 200 day simple moving average is $5.01.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.